Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 4Thoracic 3Genitourinary 2Tumor-Agnostic 1Sarcoma 1Other solid neoplasm 1Head & Neck 1

Conditions

Sarcoma 1Rhabdoid Tumor 1Chordoma 1

Interventions

Cyclophosphamide 22Specimen Handling 20Magnetic Resonance Spectroscopy 20pembrolizumab 18Nivolumab 18Radiotherapy 17Biopsy 16Doxorubicin 15Temozolomide 14Radiation 14X-Rays 9Irinotecan 9Ipilimumab 9Ifosfamide 9fludarabine 8Phantoms, Imaging 8Etoposide 8cabozantinib 7Vincristine 7Carboplatin 7Bevacizumab 7regorafenib 6Sirolimus 6palbociclib 5olaparib 5fludarabine phosphate 5durvalumab 5Vinorelbine 5Sunitinib 5Radiosurgery 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Tiragolumab × Sarcoma × Clear all
NCT05286801 2026-05-13

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
86 enrolled
Sarcoma

Chordoma, Sarcoma, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡